Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 3Gynecologic 2Dermatologic 2Thoracic 1Plasma cell 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Melanoma 2Carcinoma, Renal Cell 1

Interventions

pembrolizumab 157Nivolumab 132Ipilimumab 77Cyclophosphamide 46Specimen Handling 44Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 21fludarabine phosphate 20dabrafenib 20atezolizumab 20Radiotherapy 20Opdualag 19Radiosurgery 18CTLA-4 Antigen 18encorafenib 17aldesleukin 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lenvatinib 11Bevacizumab 11lifileucel 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glucose × Dermatologic × 1 year × Clear all
NCT06391099 2026-05-26

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Ohio State University Comprehensive Cancer Center

Phase NA Suspended
60 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT05933577 2025-09-24

V940-001

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
1,089 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡